Biomolecules & biomedicine最新文献

{"title":"Effectiveness of SGLT2 inhibitors compared to sulphonylureas for long-term glycemic control in type 2 diabetes: A meta-analysis.","authors":"Zhouhong Zhan, Jialiang Wang, Nannan Shen, Xinwen Liu, Lihong Wang","doi":"10.17305/bb.2025.12658","DOIUrl":"10.17305/bb.2025.12658","url":null,"abstract":"<p><p>Sulphonylureas (SUs) are common glucose-lowering agents used for managing type 2 diabetes mellitus (T2DM). However, their long-term effectiveness is often limited due to declining β-cell function. Sodium-glucose co-transporter 2 (SGLT2) inhibitors act independently of insulin, potentially providing more sustained glycemic control. Nonetheless, comparative data regarding the long-term glycemic durability of these two drug classes are limited. We performed a meta-analysis of head-to-head randomized controlled trials (RCTs) comparing the efficacy of SGLT2 inhibitors versus SUs in patients with T2DM already receiving metformin therapy. Eligible studies reported HbA1c values at intermediate (24-28 weeks or 48-52 weeks) and final (96-104 weeks or 208 weeks) time points, with a minimum follow-up duration of 96 weeks. Pooled mean differences (MD) and their 95% confidence intervals (CIs) were calculated using random-effects models. Seven comparisons from five RCTs were included in our analysis. Compared with SUs, SGLT2 inhibitors were associated with significantly smaller increases in HbA1c over time. From 24-28 weeks to 96-104 weeks, the pooled MD was -0.28% (95% CI: -0.35 to -0.20; p < 0.001; I² = 0%). From 48-52 weeks to 96-104 weeks, the MD was -0.11% (95% CI: -0.19 to -0.04; p = 0.004; I² = 0%). In longer-term analyses, SGLT2 inhibitors demonstrated sustained benefits from 52 weeks to 208 weeks (MD: -0.22%; 95% CI: -0.34 to -0.10; p < 0.001) and from 104 weeks to 208 weeks (MD: -0.12%; 95% CI: -0.25 to -0.01; p = 0.04). Overall, SGLT2 inhibitors provide superior glycemic durability compared to SUs in patients with T2DM, supporting their preferential use as a second-line therapy after metformin.</p>","PeriodicalId":72398,"journal":{"name":"Biomolecules & biomedicine","volume":" ","pages":"285-294"},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12505523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of genome-wide DNA methylation and polymorphisms in periodontitis etiology: A narrative review.","authors":"Elena Jovanova, Angela Angjelova, Alessandro Polizzi, Gaetano Isola","doi":"10.17305/bb.2025.12646","DOIUrl":"https://doi.org/10.17305/bb.2025.12646","url":null,"abstract":"<p><p>Periodontitis is a multifactorial inflammatory disease influenced by genetic, epigenetic, and environmental factors. Recent advancements in genomic and epigenomic research have highlighted the role of genetic polymorphisms and genome-wide DNA methylation in its pathogenesis. DNA methylation regulates gene expression, affecting immune responses and inflammatory pathways, while genetic polymorphisms may predispose individuals to altered host-microbial interactions and increased susceptibility to periodontal destruction. Recent studies have identified promising periodontal biomarkers, including specific genetic and epigenetic markers, that may aid in early diagnosis, risk assessment, and monitoring of disease progression. This narrative review synthesizes current evidence on the genetic and epigenetic mechanisms involved in the etiology of periodontitis, with a focus on genome-wide DNA methylation and genetic polymorphisms. It also explores their potential implications for disease pathogenesis, diagnostics, and therapeutic strategies. Future research directions include integrative multi-omics approaches to better understand the complex interplay between genetic, epigenetic, and environmental factors. Such efforts aim to support the development of personalized therapeutic strategies. Overall, this review underscores the critical role of genetic and epigenetic mechanisms in the pathogenesis of periodontitis and emphasizes the need to translate these findings into clinical practice through molecular diagnostics and personalized treatment approaches.</p>","PeriodicalId":72398,"journal":{"name":"Biomolecules & biomedicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic impact of pan-immune inflammation value in small-cell lung cancer treated with chemoradiotherapy and prophylactic cranial irradiation.","authors":"Aybala Nur Ucgul, Huseyin Hazir, Huseyin Bora","doi":"10.17305/bb.2025.12669","DOIUrl":"10.17305/bb.2025.12669","url":null,"abstract":"<p><p>Determining prognosis is crucial for treatment selection, especially for prophylactic cranial irradiation (PCI), in patients with limited-stage small cell lung cancer (LS-SCLC). This study evaluates the prognostic value of the pan-immune inflammation value (PIV) in patients with LS-SCLC. We included patients who underwent thoracic chemoradiotherapy (TRT) and PCI at our clinic between July 2012 and April 2024. PIV was calculated as (neutrophil count × platelet count × monocyte count) / lymphocyte count. Receiver operating characteristic (ROC) curve analysis was used to determine the optimal pre-treatment PIV cut-off to divide patients into two groups. Survival outcomes between these groups were compared using Kaplan-Meier analysis and log-rank tests. Multivariate analyses were conducted using Cox regression. Fifty-nine patients were included in the study. The optimal PIV cut-off was identified as 911 (AUC: 0.60, Sensitivity: 0.31, Specificity: 0.94, J-index: 0.26). Patients were grouped based on PIV levels: low (<911) and high (≥911). Lower PIV levels were significantly associated with improved overall survival (OS) (39 months vs. 10 months, p < 0.001) and intracranial progression-free survival (ICPFS) (not reached vs. 15 months, p < 0.001). The independent prognostic value of PIV was confirmed in multivariate analyses for both OS (p < 0.001) and ICPFS (p < 0.001). These findings suggest that pre-treatment PIV is an independent prognostic marker in LS-SCLC patients undergoing TRT and PCI.</p>","PeriodicalId":72398,"journal":{"name":"Biomolecules & biomedicine","volume":" ","pages":"2658-2665"},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12461269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vitamin D supplementation for tuberculosis prevention: A meta-analysis.","authors":"Sheng Liu, Tianyu Lin, Yanyu Pan","doi":"10.17305/bb.2025.12527","DOIUrl":"https://doi.org/10.17305/bb.2025.12527","url":null,"abstract":"<p><p>Vitamin D plays an important role in immune regulation, prompting interest in its potential for preventing tuberculosis. However, clinical findings regarding its protective effects against tuberculosis infection and disease remain inconsistent. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to assess the impact of vitamin D supplementation on the prevention of tuberculosis infection and the progression to active tuberculosis. We searched PubMed, Embase, Cochrane Library, and Web of Science databases through January 2025. Eligible studies involved participants without active tuberculosis at baseline and reported outcomes related to tuberculosis. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using a random-effects model. Subgroup and sensitivity analyses were conducted, and the certainty of evidence was evaluated using the GRADE approach. Six RCTs, involving 15,677 participants, met our inclusion criteria. Compared to placebo, vitamin D supplementation did not significantly reduce the risk of tuberculosis infection (5 RCTs; OR: 0.95; 95% CI: 0.79-1.14; p = 0.55) or the development of active tuberculosis (4 RCTs; OR: 0.77; 95% CI: 0.56-1.05; p = 0.10). The certainty of evidence was moderate for both outcomes. Subgroup analyses based on baseline vitamin D levels and duration of follow-up yielded consistent results. The incidence of serious adverse events was comparable between the vitamin D and placebo groups (OR: 1.02; 95% CI: 0.76-1.38; p = 0.87), and none of the serious events were attributed to vitamin D supplementation. In conclusion, vitamin D supplementation does not significantly reduce the risk of tuberculosis infection or progression to active tuberculosis, although it is safe and well tolerated.</p>","PeriodicalId":72398,"journal":{"name":"Biomolecules & biomedicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of telomere maintenance genes as a predictive biomarker for colorectal cancer immunotherapy response and prognosis.","authors":"Zhikai Wang, Chunyan Zhao, Yifen Huang, Chong Li","doi":"10.17305/bb.2025.12053","DOIUrl":"10.17305/bb.2025.12053","url":null,"abstract":"<p><p>Colorectal cancer (CRC) represents a significant global health challenge. Although telomere maintenance plays a crucial role in tumorigenesis, the prognostic value and immunotherapeutic relevance of telomere maintenance genes (TMGs) in CRC remain poorly understood. In this study, relevant data were retrieved from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases. TMG scores were calculated using the single-sample gene set enrichment analysis (ssGSEA) method, and TMGs associated with prognosis were subsequently identified. TCGA-CRC samples were classified into subtypes via consensus clustering (ConsensusClusterPlus). A risk prediction model was then constructed using univariate and Lasso Cox regression analyses. Survival analysis was performed using Kaplan-Meier curves generated with the survival package. Key genes were validated in vitro using cellular models. Immune cell infiltration was evaluated through ssGSEA, TIMER, and MCP-Counter tools, and chemotherapy responses were predicted using the pRRophetic package. From 28 prognosis-related TMGs, two distinct CRC subtypes were established, with subtype C1 demonstrating more favorable clinical outcomes. Additionally, a risk model incorporating seven TMG-related genes (CDC25C, CXCL1, RTL8C, FABP4, ITLN1, MUC12, and ERI1) was developed for CRC prognosis. Differential mRNA expression levels of these genes were confirmed between CRC cell lines and normal control cells. Furthermore, silencing MUC12 suppressed CRC cell migration and invasion in vitro. Importantly, CRC patients classified as low-risk exhibited superior responses to immunotherapy, whereas high-risk patients showed increased sensitivity to conventional anti-cancer treatments. This study represents the first systematic evaluation of TMGs in CRC prognosis and immunotherapy, providing novel insights that could inform personalized therapeutic strategies.</p>","PeriodicalId":72398,"journal":{"name":"Biomolecules & biomedicine","volume":" ","pages":"2696-2711"},"PeriodicalIF":0.0,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12461268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drosophila melanogaster models for investigating inflammatory bowel disease: Methods, pathology, mechanisms, and therapeutic approaches.","authors":"Xinyi Li, Shushen Sun, Xiaoxi Liu, Qinghao Meng, Mengzhe Tian, Jingyi Li, Suxia Ren, Zengyi Huang, Yiwen Wang, Shaoshan Du","doi":"10.17305/bb.2025.12656","DOIUrl":"10.17305/bb.2025.12656","url":null,"abstract":"<p><p>Inflammatory bowel disease (IBD) is a complex disorder characterized by chronic gastrointestinal inflammation. This paper examines the use of Drosophila melanogaster as a model organism to investigate interactions among the gut microbiota, intestinal stem cells (ISCs), and signaling pathways involved in IBD pathogenesis. Key findings indicate that dysbiosis of the gut microbiota significantly contributes to IBD by altering immune responses and inflammatory signaling, leading to increased intestinal damage. Additionally, ISCs are crucial for intestinal regeneration; their dysregulation exacerbates injury, highlighting their role in maintaining gut homeostasis. Natural compounds, particularly those derived from traditional herbal medicines, show promise in alleviating IBD symptoms by targeting oxidative stress, regulating inflammation, and modulating autophagy, thus promoting ISC homeostasis and restoring microbial balance. This review underscores the intricate relationships among the gut microbiota, ISCs, and inflammatory pathways in IBD, as elucidated through Drosophila studies. The studies summarized here emphasize the need to address microbial imbalances, ISC dysregulation, and inflammatory mechanisms to develop effective therapeutic strategies. Further research is essential to fully elucidate these interactions and inform innovative treatments that improve patient outcomes in IBD management.</p>","PeriodicalId":72398,"journal":{"name":"Biomolecules & biomedicine","volume":" ","pages":"186-199"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12505527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a novel clinical prediction model for sepsis related mortality by combining NEWS, PIRO and lactate.","authors":"Ozge Kurtkulagi, Ece Unal Cetin, Fatih Kamis, Murat Das, Esen Simsek, Ozgur Kurtkulagi, Adil Ugur Cetin, Yavuz Beyazit","doi":"10.17305/bb.2025.12562","DOIUrl":"10.17305/bb.2025.12562","url":null,"abstract":"<p><p>Prognostic assessment plays a crucial role in guiding therapeutic decision-making for patients with sepsis, particularly in intensive care settings. This study aimed to develop a multivariable model to predict 28-day mortality among intensive care unit (ICU) patients with sepsis by integrating serum lactate levels, the National Early Warning Score (NEWS), and the Predisposition, Infection, Response, and Organ Dysfunction (PIRO) score. Demographic information, clinical characteristics, and laboratory findings routinely collected at ICU admission were used to calculate the NEWS and PIRO scores for each patient. Patients were categorized as survivors or non-survivors based on their outcome. Both logistic regression and Cox proportional hazards models were applied for mortality prediction analysis. The final analysis included 205 patients diagnosed with sepsis (mean age: 73.6 ± 13.2 years; 53.2% male), of whom 109 died during hospitalization. Logistic regression analysis revealed that lactate, NEWS, and PIRO scores were independently associated with 28-day mortality. Combining lactate levels with NEWS and PIRO significantly enhanced mortality prediction, with the greatest accuracy observed when all three parameters were integrated. Pairwise analyses demonstrated that adding lactate to the base model significantly improved predictive accuracy (DBA: -0.103, p = 0.003), and incorporating lactate into a model already including NEWS further enhanced its predictive value (DBA: -0.042, p = 0.037). In conclusion, serum lactate measured at initial ICU admission provides valuable prognostic information for predicting 28-day mortality in sepsis patients. Furthermore, combining lactate levels with NEWS and PIRO scores substantially enhances the accuracy of mortality prediction in these patients.</p>","PeriodicalId":72398,"journal":{"name":"Biomolecules & biomedicine","volume":" ","pages":"2570-2577"},"PeriodicalIF":0.0,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12452128/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pirfenidone reduces ovarian fibrosis and improves PCOS in letrozole-induced rat model.","authors":"Ayşe Çakır Gündoğdu, Neziha Senem Arı, Ahmet Koçak, Gülnihal Şenol, Asiye Höbel, Ömer Eldiven, Fatih Kar, Orhan Özatik","doi":"10.17305/bb.2025.12676","DOIUrl":"10.17305/bb.2025.12676","url":null,"abstract":"<p><p>Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder characterized by cystic ovarian morphology, anovulation, and infertility. Ovarian fibrosis has recently emerged as a key pathological feature of PCOS. This study investigated whether pirfenidone (PFD), an antifibrotic agent, could improve ovarian dysfunction in a letrozole-induced PCOS rat model. Forty-two female Wistar albino rats were divided into six groups (n=7 each): control, PFD, PCOS, PCOS/PFD, PCOS/combined oral contraceptives (COC), and PCOS/PFD/COC. PCOS was induced using letrozole (1 mg/kg/day orally for 21 days). PFD (200 mg/kg/day) and/or COC (0.18 mg/kg cyproterone acetate and 0.00315 mg/kg ethinyl estradiol) were administered for 21 days. Compared to controls, PCOS rats exhibited significant disruptions in estrous cyclicity, ovarian morphology, and fibrosis-related markers (all p<0.0001), despite no significant changes in testosterone (p=0.058) or estrogen (p=0.896) levels. PFD treatment significantly improved estrous cyclicity, follicular profile, and corpora lutea count (all p<0.0001), reduced ovarian fibrosis (p<0.0001), downregulated TGF-β1, CTGF, and MMP-9 (all p<0.0001), and upregulated PPAR-γ and MMP-2 (both p<0.0001), without affecting hormone levels (p=0.945 and p=0.479, respectively). COC treatment also improved estrous cyclicity and ovarian histology (all p<0.0001), reduced fibrosis (p=0.005), and modulated TGF-β1, CTGF, MMP-9, and PPAR-γ expression (p=0.0001 to <0.0001), but had no effect on MMP-2 (p=0.868). Combination therapy (PCOS/PFD/COC) provided additional improvement in corpora lutea count (p<0.0001 vs. PCOS/PFD) and collagen deposition (p=0.002 vs. PCOS/PFD) but did not confer further benefits in fibrosis-related marker expression or folliculogenesis (all p>0.05). These findings suggest that pirfenidone mitigates PCOS pathology by targeting ovarian fibrosis, supporting antifibrotic therapy as a novel and promising approach.</p>","PeriodicalId":72398,"journal":{"name":"Biomolecules & biomedicine","volume":" ","pages":"2558-2569"},"PeriodicalIF":0.0,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12452129/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing predictions of health insurance overspending risk through hospital departmental performance indicators.","authors":"Yao Bu, Danqi Wang, Xiaomao Fan, Jiongying Li, Lei Hua, Lin Zhang, Wenjun Ma, Liwen He, Hao Zang, Haijun Zhang, Xingyu Liu, Yufeng Gao, Li Liu","doi":"10.17305/bb.2025.12051","DOIUrl":"10.17305/bb.2025.12051","url":null,"abstract":"<p><p>The substantial rise in health insurance expenditures, combined with delayed feedback on overspending from administrative departments, highlights the urgent need for timely reporting of such data. This study analyzed a large cohort of 549,910 discharged patients' medical records from the Wuxi Health Commission, covering the period from January 2022 to November 2023. We applied four widely recognized machine learning techniques-Logistic Regression (LR), LightGBM, Random Forest (RF), and Artificial Neural Networks (ANN)-alongside departmental performance indicators (DPIs) to develop Insurance Overspending Risk Prediction (IORP) models at both regional and hospital levels. The dataset was divided into training and testing sets in a 7:3 ratio. Experimental results showed that LightGBM outperformed the other models, achieving an accuracy of 0.82 for both regional and hospital-level predictions. Its weighted F1-score reached 0.78 at the regional level and 0.82 at the hospital level, with corresponding AUC-ROC (Area Under the Receiver Operating Characteristic Curve) values of 0.91 and 0.94, demonstrating strong performance in identifying overspending risks. The model's high recall and precision further ensure reliable predictions and minimize misclassifications. Notably, four key DPIs-Total Amount of Discharged Patients (TADP), Average Inpatient Stay (AIS), Medicine Expenses Percentage (MEP), and Consumable Expenses Percentage (CEP)-were strongly correlated with overspending risks. The integration of IORP models into the Health Insurance Management System (HIMS) at the Affiliated Hospital of Jiangnan University has significantly improved departmental managers' ability to anticipate overspending. By effectively leveraging HIMS in combination with this advanced model, managers can perform timely, accurate assessments, thereby enhancing financial oversight and resource allocation.</p>","PeriodicalId":72398,"journal":{"name":"Biomolecules & biomedicine","volume":" ","pages":"2269-2280"},"PeriodicalIF":0.0,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12451977/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From BJBMS to Biomolecules and Biomedicine: A new chapter.","authors":"Faruk Skenderi, Lamija Mlaco, Muzafer Mujic, Semir Vranic","doi":"10.17305/bb.2025.12867","DOIUrl":"10.17305/bb.2025.12867","url":null,"abstract":"<p><p>The scientific community is continually evolving, driven by advancements, shifting priorities, and growing demands for global dissemination of knowledge. A clear example of successfully adapting to these demands is the transition from the Bosnian Journal of Basic Medical Sciences (BJBMS) to Biomolecules and Biomedicine (BB) in 2023. This strategic move symbolizes a significant step forward, expanding the journal's global reach and scientific scope. Read more in the PDF.</p>","PeriodicalId":72398,"journal":{"name":"Biomolecules & biomedicine","volume":" ","pages":"2148-2150"},"PeriodicalIF":0.0,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12451980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144555983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}